Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Konstantinos Syrigos, PhD
Advertisement
Articles by Konstantinos Syrigos, PhD
Advertisement
Latest Updated Articles
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETsPublished: July 10th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
4
Examining the Full Scope of Future Advancements in Radiation Oncology
5
